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Type I hypersensitivity reactions to intravenous administration of etoposide are extremely rare. Etoposide is an essential
component of several chemotherapy regimens used in gynecologic oncology, and discontinuation of this drug during a course
of treatment should only be due to severe patient intolerance. We report the successful use of intravenous etoposide phosphate as
a substitute drug in a patient with a yolk sac tumor who manifested a Type I hypersensitivity to intravenous etoposide. The patient
ultimately completed all 4 cycles of bleomycin, etoposide, cisplatin (BEP) using etoposide phosphate as a substitute drug.
1.Introduction
Hypersensitivity reaction to intravenous etoposide is a rare
side eﬀect and is infrequently reported in the medical liter-
ature. Etoposide is an essential component of chemotherapy
for patients with rare gynecologic malignancies such as germ
cell tumors and gestational trophoblastic disease, In young
patients for whom etoposide-containing regimens are given
with curative intent, omitting etoposide from regimens such
asBEP(bleomycin,etoposide,cisplatin)orEMA-CO(etopo-
side, methotrexate, actinomycin D, cyclophosphamide, vin-
cristine) may compromise eﬃcacy, necessitating second-line
therapy. There are no suitable substitutes for etoposide in
these regimens that have demonstrably similar response
rates. We report the ﬁrst documented case in the gynecologic
literature of a severe type I hypersensitivity reaction to
etoposide in a woman being treated for a yolk sac tumor
successfully treated with etoposide phosphate.
2.Case
A 25 year old with stage IC yolk sac tumor was admitted to
the hospital for her ﬁrst cycle of BEP. She was premedicated
with decadron, ondansetron, and acetaminophen. Within
minutes of the etoposide infusion the patient reported
shortness of breath, pruritus, and developed a rash on her
face and chest. The patient became hypertensive and desatu-
rated to 86% on pulse oximetry. The infusion was stopped
after only 5mL of etoposide had been administered. She
was supplemented with oxygen and given diphenhydramine
and decadron intravenously, which resolved her symptoms
rapidly. The patient was rechallenged after administration
of additional corticosteroids. The etoposide infusion was
initiated at half the original rate and again the patient
immediately developed shortness of breath, ﬂushing, and
hypoxia. The infusion was stopped and the patient’s symp-
toms resolved.
The following day the patient received an equivalent
dose of IV etoposide phosphate, a water-soluble ester of
etoposide after premedication with ranitidine (50mg IV),
diphenhydramine (50mg IV), and hydrocortisone (100mg
IV). The patient tolerated the infusion well and did not
exhibit any further hypersensitivity symptoms. The patient
completed the prescribed four cycles of BEP using etoposide
phosphate with the same regimen of premedication without
incident, and is currently free of disease.
3. Discussion
A type I hypersensitivity reaction to the IV administration
of etoposide is an unusual event impacting less than 1% of
patients. The etiology is unknown, although it is speculated2 Case Reports in Obstetrics and Gynecology
that patients are reacting to the polysorbate 80 used to
dissolve etoposide. There have been no documented cases
of a hypersensitivity reaction to the administration of oral
etoposide, and in animal models, reaction to polysorbate
have been demonstrated to result in the release of histamine
[1]. Etoposide phosphate is a water soluble prodrug of
etoposide, and this variant does not require polysorbate
80 to enter solution. To date no hypersensitivity reaction
to etoposide phosphate has been documented [2]. There
are few case reports in the literature supporting the use
of etoposide phosphate in patients with a hypersensitivity
reaction to etoposide [3, 4]. This is the ﬁrst case report in the
gynecologic literature of a patient with a yolk sac tumor and
a type I hypersensitivity reaction to etoposide successfully
treated with 4 cycles of IV etoposide phosphate.
Although infrequently used by gynecologic oncologists,
etoposide is an important agent in treating rare and aggres-
sive gynecologic malignancies. Eliminating etoposide in this
regimen would likely negatively impact this patient’s poten-
tial for a cure. Alternative strategies included desensitization:
increasing the dose of steroid premedication and slowing the
rate of infusion, but these strategies failed in our patient.
Consideration was given to substituting oral etoposide.
However, there is no data in the gynecologic or testicular
cancer literature to support this and may have compromised
her chance of cure. The use of second-line chemotherapy
such as VAC (vincristine, adriamycin, cyclophosphamide)
was also considered but given the lower response rate this
strategy was abandoned. The use of etoposide phosphate in
this setting seemed wise.
We were able to successfully complete four cycles of BEP
using etoposide phosphate, a water soluble prodrug form of
etoposide.WeinitiallypremedicatedourpatientwithH1and
H2 blockers and 100mg of IV hydrocortisone 15 minutes
before and repeated the hydrocortisone dose immediately
following infusion. After successfully completing the ﬁrst
cycle of therapy, we premedicated with diphenhydramine,
ranitidine, and hydrocortisone prior to infusing the etopo-
side phosphate. The patient tolerated treatment without
further incident.
Based on our experience with etoposide phosphate in
this patient, we have created a protocol for its use in the
setting of hypersensitivity reactions. While an extremely
rare side eﬀect to the infusion of etoposide, hypersensitivity
reactions present a therapeutic challenge with few viable
alternatives. Etoposide phosphate, however, appears to be a
suitable alternative and should be considered the alternative
drug of choice for patients with a hypersensitivity reaction to
IV etoposide.
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